Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2013, Vol. 18 ›› Issue (5): 570-575.

Previous Articles     Next Articles

New insights of the reasonable application of clinical drugs on the treatment for lupus nephritis

YAN Shang-xue1, DENG Xiao-mei1, XU Xing-ming2, WEI Wei1   

  1. 1Institute of Clinical Pharmacology, Anhui Medical University,Key Laboratory of Immune Medicine(Anhui Medical University), Ministry of Education, Ministry of Education, Hefei 230032,Anhui, China;
    2Department of Nephrology, the First Affilicated Hospital of Anhui Medical University,Hefei 230022,Anhui, China
  • Received:2012-08-13 Revised:2012-11-30 Online:2013-05-26 Published:2013-05-22

Abstract: Kidney damage remains one of the most devastating complications of systematic lupus erythematosus (SLE). Lupus nephritis(LN) is the major cause of morbidity and mortality in patients with SLE. The treatment protocol for LN is emphasized to use induction and maintenance therapies sequentially according to the pathological types. The combination of immunosuppressant and glucocorticoid therapy is the major project on clinical treatment for LN patients. With the development of modern medical technology and the deep explore of the pathogenic of LN, the treatment strategy of LN has been improved significantly and the survival of the patients has obviously increased. Herein the new insights about the treatment for LN are reviewed.

Key words: Lupus nephritis, Clinical drugs, Reasonable application

CLC Number: